New in NAR Cancer: Colón-Rios, Glazer, and coworkers model PARPi resistance in the IDH1-mutant setting and offer a strategy to overcome resistance by treating with the receptor tyrosine kinase inhibitor, cediranib - mechanism involves suppression of re-activated HDR factors. doi.org/10.1093/narc...

Fantastic speaker lineup, co-organized by NAR Cancer Editorial Board member John Tainer. One of a select few conferences that NAR Journals will extend sponsorship to this year.

James Watson, Co-Discoverer of the Structure of DNA, Is Dead at 97 www.nytimes.com/2025/11/07/s...

Excited to share: NAR Cancer Editor's Choice review article from Kyungjae Myung and colleagues provides a snapshot of the blossoming field of DNA damage response- and repair-targeted therapeutics. Focus is on small molecules currently in clnical trials. academic.oup.com/narcancer/ar...

Congratulations to Forment, O’Connor and coworkers on an Editors' Choice study in NAR Cancer, unraveling the mechanism by which addition of PARP inhibitors to AR pathway inhibitor therapy improves prostate cancer survival, even in the absence of HRR defects. academic.oup.com/narcancer/ar...

New in NAR Cancer: Loss of uL14 downregulates antigen processing and presentation components in melanoma cell lines - alters peptide pool available for presentation to create an escape mechanism from immune surveillance. From Anna Dopler and coworkers.

Evaluation of 49 mRNA modification regulators across subtypes in human breast cancer reveals potential biomarkers and therapeutic targets. New in NAR Cancer, from Carlos Paula, Erik Dassi, Francesca Aguilo and coworkers at University of Trento and Umeå University. academic.oup.com/narcancer/ar...

We described Ku-RNA binding in 1998, but had to wait 27 years for Zha and coworkers to discover the significance. A lesson in patience. 2/2 pubs.acs.org/doi/10.1021/...

Congrats to our Editorial Board member Shan Zha for amazing study attributing essentiality of Ku protein in primates to modulation of RNA-driven innate immunity. 1/2 www.nature.com/articles/s41...

N6-methyladenosine in R-loop homeostasis. Short review in NAR Cancer from Chun-Long Chen and coworkers. Effects on transcription, repair, centromere and telomere stability, and R-loop dynamics. Targeting as a cancer therapeutic strategy. academic.oup.com/narcancer/ar...

Beyond BRCA status: machine-learning assisted multichannel imaging platform for cell-by-cell analysis of HR competency, enabling patient stratification. “Editor’s Choice” in NAR Cancer. academic.oup.com/narcancer/ar...

New insights into gene regulation in melanoma, the deadliest skin cancer: SETD6-catalyzed methylation of BRD4 and chromatin-localized interaction with MITF. From Tzofit Elbaz Biton, Dan Levy, and coworkers, published in NAR Cancer. academic.oup.com/narcancer/ar...

Our sister journal, Nucleic Acids Research, has opened a search for an Executive Editor. Great opportunity for mid-career or senior investigator looking to be part of a great team, handle 100-150 papers per year, and attend the annual EE meeting. Details at: academic.oup.com/nar/pages/ex...

Are key cancer driver mutations amenable to editing by endogenous ADAR enzymes? The scope of correctable mutations is charted for the first time in an Editor's Choice paper, newly published in NAR Cancer. From Rona Merdler-Rabinowicz and colleagues. academic.oup.com/narcancer/ar...

New in NAR Cancer. A critical examination of mutations in conserved m6A motifs: low recurrence and maybe not a primary mechanism for altering gene function. From Luis A. Diaz and coworkers, @mskcancercenter.bsky.social academic.oup.com/narcancer/ar...

Watch the replay of Elise Fouquerel and Rob Sobol's talks at today's NAR Cancer 5th anniversary symposium (offered in collaboration with Social DNAing). Special thanks to guest host Li Lan. Link to video at the Social DNAing website: www.cancer.columbia.edu/research/pro...

NAR Cancer 5th anniversary symposium on manipulating DNA repair and DDR for cancer therapy - 4th and final session, Thursday April 17, noon Eastern. Elise Fouquerel and Rob Sobol on emerging targets. Link to free registration: academic.oup.com/narcancer/pa...

Replay of two great talks from last week's NAR Cancer 5th anniversary symposium on manipulating the DNA damage response. Dale Ramsden on DNA polymerase theta - what it repairs and when, and Katie Pawelczak on a first-in-class RPA inhibitor. Find the link at www.cancer.columbia.edu/research/pro...

NAR Cancer 5th Anniversary symposium in cooperation with Social DNAing: Thursday, March 13, noon US Eastern. Dale Ramsden on Pol theta and Katie Pawelczak on targeting RPA. Program info and link to register: academic.oup.com/narcancer/pa...

Novel approach for simultaneous profiling of long-range genetic and epigenetic changes in matched cancer samples, focusing on clear cell renal cell carcinoma. New in NAR Cancer. From Sapir Margalit, Yuval Ebenstein, and others, Tel Aviv University. academic.oup.com/narcancer/ar...

New Cancer Grand Challenges announced: mechanisms driving unassigned mutational signatures, the dark proteome, and more: www.cancergrandchallenges.org/new-challeng...

Reaching out to #earlycareerinvestigators @narjournal.bsky.social

First in vivo DNA aptamer selection using an orthotopic patient-derived xenograft glioblastoma mouse model to identify tumor-homing DNA aptamers. From Caroline Doherty, LJ Maher and colleagues at Mayo Clinic. New in NAR Cancer. academic.oup.com/narcancer/ar...

New in NAR Cancer - Use of human artificial chromosome (HAC)-based assay to analyze chromosomal instability in IDH-mutant gliomas suggests a precision medicine approach to improve therapeutic outcomes - from Goncharov and coworkers. academic.oup.com/narcancer/ar...

In NAR Cancer: Loss of powerful G4 resolvase FANCJ sensitizes to G4-stabilizing ligand - shown in cancer cells and in C. elegans in vivo. Proof-of-principle for synthetic lethality-based therapeutic approach. Marcello Germoglio et al, IBBC and University of Naples. academic.oup.com/narcancer/ar...

Watch the replay - terrific and well attended talks from Kara Bernstein (RAD51 paralogs) and Joanna Loizou (pol theta) yesterday at the NAR Cancer 5th anniversary symposium. Link to "watch the latest replay" at www.cancer.columbia.edu/research/pro...

This is terrific to see! Proud graduate student Dory Fawwal presents her new NAR Cancer paper to her peers and colleagues. Oncohistone H3E50K. academic.oup.com/narcancer/ar...

NAR Cancer 5th anniversary symposium on manipulating DNA repair and the DDR - Session 2 this Thursday, Feb 13, noon US Eastern time. Kara Bernstein and Joanna Loizou speaking. In collaboration with Social DNAing. Information and free registration link at academic.oup.com/narcancer/pa...

NAR Cancer 5th anniversary symposium with Social DNAing - Manipulating DNA repair for cancer therapy. 2nd session Feb. 13. Kara Bernstein (Penn) on insights from HR variants and Joann Loizou (ICR) on Pol theta gap processing and fork progression. Register at: columbiacuimc.zoom.us/webinar/regi...

New in NAR Cancer: Oncogenic histone variant H3E50K changes chromatin accessibility, dysregulates gene expression, and supports an EMT phenotype. From Kirti Sad, Anita Corbett, Jennifer Spangle and colleagues at Emory University Winship Cancer Institute. academic.oup.com/narcancer/ar...

Encourage reading Keith Caldecott's obituary for Larry Thompson, published in the February issue of DNA repair - "A life of bikes, birds, and DNA repair (1941-2024). doi.org/10.1016/j.dn...

More in our series on Translation and Cancer. In cancer cell lines and primary breast tumors, EMT factor ZEB1 modulates site-specific 2'-O-methylation of 28S rRNA, correlated to perturbation of snoRNA expression. From Chloé Morin, Virginie Marcel and others. academic.oup.com/narcancer/ar...

Nucleic Acids Research has arrived on Bluesky! Follow them for the latest on biology and biochemistry of nucleic acids and proteins with which they interact. Run by scientists for scientists and a pioneer in Open Access. @narjournal.bsky.social

Pleased to announce NAR Cancer is now indexed in Medline - articles are searchable with MeSH terms. After five years of publication we’ve made the big time. Woo-hoo!

New in NAR Cancer - The Atlas of Protein-Protein Interactions in Cancer (APPIC)-a webtool that aggregates data from multiple sources to provide comprehensive insights. From Ece Uzun and coworkers at Brown University academic.oup.com/narcancer/ar...

NAR Cancer 5th anniversary symposium - fantastic first session today. Ranjit Bindra on development of innovative peptide-drug conjugate CBX-12 and Li Lan on RNA methyltransferase TRDMT1 as an emerging target. Recordings available for a limited time: fast.wistia.com/embed/channe...

NAR Cancer 5th anniversary symposium: Manipulating DNA repair and the DNA damage response to improve cancer therapy. First session via Zoom this week, Jan 9, noon US Eastern features Ranjit Bindra (Yale), Li Lan (Duke). Register at columbiacuimc.zoom.us/webinar/regi...

New in NAR Cancer: Spatial transcriptomics in breast cancer reveals TME-driven drug responses and clonal therapeutic heterogeneity. From Fátima Al-Shahrour and coworkers, CNIO Madrid. academic.oup.com/narcancer/ar...

Landmark review article in Nucleic Acids Research addresses classic question of RNAP II termination in metazoans.

Announcing the NAR Cancer virtual 5th anniversary symposium: "Manipulating DNA repair and the DNA damage response to improve cancer therapy." First webinar Jan 9. In cooperation with Social DNAing at Columbia University. Read the program and register for free! academic.oup.com/narcancer/pa...

Interested in rRNA modification? Join RiboMod2025 in Bologna, 12-13 June 2025. Dedicated to standardizing studies of snoRNA and snoRNA-guided ribosomal RNA modification. Speakers/organizers include NAR Cancer authors Jean-Jacques Diaz, Virginie Marcel, Lorenzo Montanaro. events.unibo.it/ribomod2025

Revisiting a classic problem indeed!

New at NAR Cancer: Ex vivo functional test for HR proficiency applied to a cohort of ovarian cancer PDX models: a way to identify PARPi-sensitive tumors lacking BRCA1/2 alterations. From Francien Talens et al., Univ of Groningen. academic.oup.com/narcancer/ar...

Very cool to see commitment to reconstitution.

Read our latest: new insights into regulation of N6-methyladenosine modification of mRNA: three YTHDF parlous and VIRMA are strong cross-histotype tumor driver candidates. From @erikdassi.bsky.social , Alessandro Quattrone, and coworkers, University of Trento. academic.oup.com/narcancer/ar...

NAR Cancer is on Bluesky Social! Open Access with a unique scope at the intersection of the cancer and nucleic acids fields. Run by scientists for scientists, associated with quality impactful research, part of the NAR family of journals at Oxford University Press. academic.oup.com/narcancer/pa...